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Abstract
Background: The purpose of this study was to evaluate the AJCC eighth edition
clinical staging system for human papillomavirus (HPV)-associated oropharyngeal
squamous cell carcinoma and to further understand how clinical stage and smoking
history affect oncologic outcomes. The purpose of this study was to present the
understanding of how clinical stage and smoking history affect oncologic outcomes
in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma
(SCC) is critical for selecting patients for treatment deintensification.
Methods: Kaplan-Meier and Cox regression were used to evaluate overall survival
(OS), locoregional recurrence-free survival (LRFS), and distant recurrence-free survival
(DRFS). Concordance statistics (C-indices) were used to compare discriminating ability.
Results: The OS and DRFS but not LRFS were significantly distributed using the
American Joint Committee on Cancer (AJCC) seventh and eighth editions criteria.
The C-indices for OS, LRFS, and DRFS were 0.57, 0.54, and 0.60, respectively,
using the AJCC seventh edition, and 0.63, 0.53, and 0.65, respectively, using the
AJCC eighth edition. On multivariate analysis, 11 pack-year smoking history corre-
lated with OS (hazard ratio [HR] 1.96; 95% confidence interval [CI] 1.2-3.1; P< .01)
but not LRFS or DRFS.
Conclusion: These results support implementation of the AJCC eighth edition for
HPV-associated oropharyngeal SCC. Clinical stage may be more important than
smoking history in selection for deintensification.
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1 | INTRODUCTION
Although oropharyngeal squamous cell carcinoma (SCC) was
historically associated with tobacco smoking and alcohol
consumption, the incidence of human papillomavirus (HPV)-
associated oropharyngeal SCC is increasing.1 Compared to
smoking-related oropharyngeal SCC, HPV-positivity is asso-
ciated with distinct clinical behavior, including improved
prognosis.2,3 Therefore, it was recognized that previous clini-
cal staging systems, including the seventh edition of the Amer-
ican Joint Committee on Cancer (AJCC) Staging Manual,
were less applicable to HPV-associated oropharyngeal
SCC.4–6 In particular, patients with HPV-positive oropharyn-
geal SCC were observed to distribute nonuniformly among
AJCC seventh edition clinical stages, which reduced prognos-
tic utility of the system.5,7 With the goal to improve risk
stratification and outcome prediction in HPV-associated oro-
pharyngeal SCC, the International Collaboration on Oropha-
ryngeal Cancer Network for Staging (ICON-S) developed a
novel clinical staging system. This system was initially devel-
oped through a retrospective study of patients treated at Prin-
cess Margaret Hospital8 and was subsequently refined and
validated in a larger, multi-institutional cohort.9 The ICON-S
clinical staging system has been adapted for widespread imple-
mentation as part of the AJCC eighth edition staging manual.10
The ICON-S and AJCC eighth edition staging systems have
been externally validated in 2 studies with cohorts of 150 and
279 patients each.11,12 As staging validation studies, these
analyses appropriately investigated prognostication of overall
survival (OS) only, and not disease-specific outcomes.
The negative effect of smoking on OS in patients with
HPV-related oropharyngeal SCC is well-recognized.9 How-
ever, it is not clear if this decreased OS is related directly to
differences in cancer-specific outcomes, as suggested by some
studies,13–15 or merely the result of smoking-related comorbid-
ities, as supported by others.16,17 In the ICON-S report and the
related preceding study, a 20 pack-year smoking history8 and
pack-years as a continuous variable9 were associated with
worse OS, although potential associations with disease-
specific outcomes were not investigated. Importantly, smoking
status was not incorporated into the AJCC eighth edition.10
Due to the relatively good prognosis associated with
HPV-positivity in oropharyngeal SCC, efforts to deintensify
treatment in these patients have been proposed and are cur-
rently under clinical investigation. Appropriate selection of
candidates for deintensification relies on accurate and indi-
vidualized risk stratification that considers not only OS, but
disease-specific outcomes as well. We sought to describe the
AJCC eighth edition staging system’s ability to predict multi-
ple cancer-specific outcomes and to investigate the impact of
smoking history in a robust cohort of patients with HPV-
associated oropharyngeal SCC.
2 | MATERIALS AND METHODS
2.1 | Patient population
Patients analyzed in this institutional review board-approved
study were seen at a single academic tertiary cancer center.
Inclusion criteria stipulated adults with biopsy-proven oro-
pharyngeal SCC, AJCC seventh edition stages I to IVb, posi-
tive for p16 by immunohistochemical staining, or, in cases in
which p16 staining was not performed, HPV DNA by poly-
merase chain reaction. Patients were treated definitively with
surgery and/or radiotherapy (RT), with or without systemic
therapy (chemotherapy or cetuximab) per institutional prac-
tices, which were consistent with the National Comprehen-
sive Cancer Network guidelines. Demographic, disease, and
treatment data were collected prospectively in a password-
protected epidemiology database. Patients provided informed
consent to be included in this database. Smoking history was
collected prospectively, with former smoking status defined
as abstinence from tobacco use for at least 1 year before
diagnosis. Patients who had quit smoking <1 year before
diagnosis were classified as current-smokers. Patients
were retrospectively restaged per the AJCC eighth edition
guidelines.
2.2 | Outcome definitions and statistical
methods
Overall survival was calculated from the date of diagnosis.
Patients alive at last follow-up were censored at that date.
Locoregional recurrence-free survival (LRFS) and distant
recurrence-free survival (DRFS) were similarly calculated from
the date of diagnosis, with patients alive without evidence of
locoregional or distant recurrence, respectively, being censored
at the date of last follow-up. Kaplan-Meier was used to com-
pare estimated rates of OS, LRFS, and DRFS. The log-rank
test was used to evaluate the significance of outcome
distribution. Concordance statistics (C-indices) were calculated
to compare the discriminating ability of each staging system.
Multivariate Cox regression, accounting for the AJCC eighth
edition clinical group stage, was used to correlate age and
smoking status with OS, LRFS, and DRFS. Age was consid-
ered as a continuous variable and smoking history was ana-
lyzed using multiple cutoffs, as detailed below.
3 | RESULTS
3.1 | Patient characteristics and staging
Five hundred thirty-one patients treated between 2003 and
2016 were identified and included in this analysis. Median
follow-up was 48 months. Patient characteristics are shown
in Table 1. Upon restaging from the AJCC seventh edition to
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the eighth edition, all but 5 patients (0.9%) were assigned a
new clinical group stage, with 13 patients (2.4%) changing
from stage II to I, 25 patients (4.7%) from stage III to I, 28
patients (5.3%) from stage III to II, 224 patients (42.2%)
from stage IVa to I, 80 patients (15.1%) from stage IVa to II,
110 patients (20.7%) from stage IVa to III, and 46 patients
(8.7%) from stage IVb to III. No patient was assigned a
higher clinical group stage upon reclassification.
3.2 | Prognostication of overall survival,
locoregional recurrence-free survival, and
distant recurrence-free survival
Kaplan-Meier estimates of OS by the AJCC seventh and
eighth editions of clinical stage are shown in Figure 1. The
log-rank test showed significant distribution of OS by the
AJCC seventh and eighth editions of stages. Kaplan-Meier
estimates of LRFS and DRFS are shown in Figure 2. Prog-
nostication of DRFS was significant by use of the AJCC sev-
enth and eighth editions of staging, although neither system
yielded significant distribution of LRFS. Actuarial rates of 5-
year OS, LRFS, and DRFS are shown in Supporting Infor-
mation Table S1. Table 2 shows hazard ratios (HRs) corre-
sponding to the AJCC eighth edition stages for each
outcome. We also attempted to calculate HRs for the AJCC
seventh edition staging. Due to low numbers of patients and
events, stages I and II were combined to create a reference
category for OS. This approach yielded HRs of 0.50 (95%
confidence interval [CI] 0.1-2.6), 0.98 (95% CI 0.2-4.0), and
2.21 (95% CI 0.5-9.6) for the AJCC seventh edition stages
III, IVa, and IVb, respectively. However, there were too few
recurrences in stages I and II to allow for estimation of HRs
for LRFS and DRFS.
TABLE 1 Patient characteristics
Characteristic No. of patients
Age, years
Mean, years (SD) 57.9 (9.1)
Median (range) 57.1 (33-91)
Female sex (%) 69 (13.0)










































Characteristic No. of patients
Treatment modalitya (%)
RT alone 14 (2.6)
Concurrent RT1 systemic therapyb 473 (89.1)
Surgery followed by concurrent
RT1 systemic therapy
21 (3.9)
Surgery followed by RT 10 (1.9)
Surgery alone 13 (2.4)
Treatment location (%)
University of Michigan only 462 (87.0)
Portion at outside facility 69 (13.0)
Abbreviations: AJCC, American Joint Committee on Cancer; HPV, human
papillomavirus; RT, radiotherapy.
aTreatment modality refers to initial, definitive treatment, excluding diagnostic
procedures, such as diagnostic tonsillectomy and excisional lymph node
biopsy, as well as subsequent salvage and palliative therapies.
bSystemic therapy refers to cytotoxic chemotherapy and/or cetuximab.
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As both the AJCC seventh edition and eighth edition
guidelines resulted in statistically significant distribution of
OS and DRFS, we sought to compare the discriminating abil-
ity of these 2 systems by calculating C-indices. Table 3
shows these results, with the AJCC eighth edition yielding
higher (better) C-indices for OS and DRFS compared to the
AJCC seventh edition.
3.3 | Impact of smoking history
In this cohort, there were no significant differences in the rel-
ative prevalence of the AJCC eighth edition T classification,
N classification, and group stages among never smokers, cur-
rent smokers, and former smokers (Supporting Information
Table S2). On multivariate analysis, accounting for clinical
group stage (per the AJCC eighth edition), age and any
smoking history (11 pack-years) were statistically signifi-
cantly correlated with OS, whereas smoking history by other
cutoffs, namely 101 pack-years, 201 pack-years, and cur-
rent smoking status, were not (Table 4). No degree of smok-
ing history was significantly associated with LRFS or DRFS.
Only age was significantly correlated with LRFS.
4 | DISCUSSION
These data confirm the improved prognostication of OS in
patients with HPV-associated oropharyngeal SCC using the
AJCC eighth edition clinical staging compared to the AJCC
seventh edition. Although both systems yielded significant
distribution of OS, the C-index associated with the AJCC
eighth edition was higher than that associated with the sev-
enth edition, indicating superior performance. This is consist-
ent with findings from the initial ICON-S studies8,9 as well
as previously published validation reports.11,12 Compared
with previous validation studies, this work analyzed a larger
cohort of prospectively collected patients and investigated
cancer-specific outcomes in addition to OS. Although the
primary goal of staging is prognostication of OS, understand-
ing how the stage predicts locoregional and distant control
can guide clinical decision making. In this regard, we found
that the AJCC eighth edition clinical staging manual showed
superior prognostication of DRFS compared to the seventh
edition; however, neither system resulted in significant LRFS
distribution. This observation is consistent with the under-
standing that in HPV-associated oropharyngeal SCC, distant
failure is a more important cause of cancer mortality than
locoregional failure, likely due to the generally excellent
locoregional control achieved in these patients.2,18–20 Inter-
estingly, the rates of distant recurrence in patients with AJCC
eighth edition stages I and II were relatively similar, whereas
patients with stage III disease demonstrated a much higher
risk.
A major criticism of the AJCC seventh edition staging
for HPV-associated oropharyngeal SCC is that patients dem-
onstrate uneven stage distribution.5–7 Specifically, a dispro-
portionately high number of patients are diagnosed with
higher stage disease, which results in poor differentiation of
outcomes. In this analysis, distribution of patients by clinical
stage was markedly different using the AJCC seventh edition
versus the AJCC eighth edition guidelines. We found that
most patients in our cohort were initially diagnosed with
stage IV disease using the AJCC seventh edition criteria, but
when retrospectively reassessed using the AJCC eighth edi-
tion, a majority were assigned an early stage. This redistribu-
tion was associated with improved stratification of OS and
DRFS.
FIGURE 1 Kaplan-Meier estimates of overall survival by the American Joint Committee on Cancer (AJCC) seventh edition and eight edition cancer
staging manuals.
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Since the earliest studies describing HPV-associated oro-
pharyngeal SCC, smoking has been consistently associated
with worse OS.2 Of particular relevance to our present work
are studies that included redefined staging for HPV-associated
disease. In the staging reclassification work preceding the
ICON-S study, Huang et al8 identified a 20 pack-year smoking
history as being associated with worse OS, particularly in
patients with early-stage disease. In the subsequent ICON-S
report, O’Sullivan et al9 identified smoking pack-years as a sig-
nificant correlate with OS on multivariate analysis. However,
neither of the 2 published validation studies found smoking to
be independently correlated with OS when using updated stag-
ing.11,12 Results from the present study demonstrate a statisti-
cally significant association between OS and a 11 pack-year
smoking history but no significant correlation using other
cutoffs, including 20 pack-years.
Although the impact of smoking on OS is relatively well-
established, it remains uncertain if this is related to mortality
from noncancer smoking-related health effects or is directly
related to oropharyngeal SCC outcomes. Certain studies have
shown higher rates of treatment failure or disease progression
in HPV-positive smokers than nonsmokers,13–15 although
others have shown no impact of smoking history on disease-
specific outcomes.16,17 In the work presented here, we found
that when accounting for stage and age, neither current smok-
ers nor former smokers were at increased risk for locoregional
or distant recurrence when compared with nonsmokers. These
findings suggest that in patients with HPV-positive disease,
smoking may impact OS primarily through mechanisms not
directly related to disease recurrence.
In the era of treatment deintensification for HPV-associated
oropharyngeal SCC, the identification of truly “low-risk”
FIGURE 2 A, B, Kaplan-Meier estimates of locoregional and C, D, distant recurrence-free survival by the American Joint Committee on Cancer
(AJCC) seventh edition and eighth edition cancer staging manuals.
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patients who may be eligible for such strategies is critical. The
most important factors considered in reported and ongoing dein-
tensification trials have been stage and smoking history. In this
setting, the impact of these variables on disease-specific out-
comes, and not solely on OS, is particularly relevant. In the East-
ern Cooperative Oncology Group study 1308, a trial of reduced-
dose RT and cetuximab in patients with complete clinical
response to induction chemotherapy, patients with nodal classifi-
cation<N2c (<N2 by the AJCC eighth edition criteria), T clas-
sification<T4, and a 10 pack-year smoking history showed
substantially better OS and progression-free survival than
patients with more advanced disease or a more significant smok-
ing history.21 Some have interpreted these results to indicate that
an extensive smoking history should exclude patients from dein-
tensified treatment. Conversely, in an analysis of patients treated
for HPV-associated oropharyngeal SCC with RT alone or con-
current chemoradiotherapy, O’Sullivan et al16 found that for
patients with a >10 pack-year smoking history, only OS, and
not cancer-specific outcomes, was decreased in patients treated
with RT alone compared to chemoradiotherapy. Some have sug-
gested that these results indicate that smoking history should not
disqualify patients from deintensification. After these results,
some subsequent studies have excluded patients with a signifi-
cant smoking history, including the Trans-Tasman Radiation
OncologyGroup 12.01 and the National ResearchGroupOncol-
ogy HN002, whereas others have not, such as the Radiation
Therapy Oncology Group 1016 and the Eastern Cooperative
Oncology Group 3311 (reviewed in Ref. 22). This lack of con-
sistency regarding smoking history as an exclusion criterion is
not surprising given the conflicting nature of the available data.
Our work indicates that smoking history may be less important
than stage in relation to disease-specific outcomes, suggesting
that treatment deintensification may be appropriate for otherwise
low-risk patients with a significant smoking history.
There are important limitations of this study that deserve
mention. Although patients were accrued prospectively,
abstraction of certain data was conducted retrospectively. This
raises issues of bias as well as data integrity and accuracy, in
TABLE 2 Kaplan-Meier estimated hazard ratio of outcomes by
American Joint Committee on Cancer seventh edition and eighth
edition clinical stage manuals
AJCC seventh and
eighth editions
OS, HR (95% CI)
Stage I Reference
Stage II 1.54 (0.8-3.0)
Stage III 4.07 (2.5-6.8)
LRFS, HR (95% CI)
Stage I Reference
Stage II 0.95 (0.5-2.0)
Stage III 1.41 (0.8-2.6)
DRFS, HR (95% CI)
Stage I Reference
Stage II 0.97 (0.4-2.3)
Stage III 3.70 (2.1-6.6)
Abbreviations: AJCC, American Joint Committee on Cancer; CI, confidence
interval; DRFS, distant recurrence-free survival; HR, hazard ratio; LRFS,
locoregional recurrence-free survival; OS, overall survival.
TABLE 3 Concordance statistics calculated for overall survival,
locoregional recurrence-free survival, and distant recurrence-free sur-
vival using the American Joint Committee on Cancer seventh edition
versus the eighth edition clinical staging criteria




Abbreviations: AJCC, American Joint Committee on Cancer; DRFS, distant
recurrence-free survival; LRFS, locoregional recurrence-free survival; OS,
overall survival.
Higher concordance statistic values indicate improved discriminating ability.
TABLE 4 Multivariate analysis, accounting for group stage (per American Joint Committee on Cancer eighth edition), correlating smoking his-
tory and age with overall survival, locoregional recurrence-free survival, and distant recurrence-free survival
OS LRFS DRFS
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value
Any smoking 1.96 (1.2-3.1) < .01 1.23 (0.7-2.2) .42 1.32 (0.8-2.3) .33
101 pack-years 1.49 (1.0-2.3) .05 1.21 (0.7-2.1) .41 1.03 (0.6-1.7) .95
201 pack-years 1.26 (0.8-2.0) .38 1.06 (0.6-1.9) .93 1.02 (0.6-1.8) .98
Current smoking 1.10 (0.7-1.8) .72 0.78 (0.4-1.5) .43 1.04 (0.6-1.9) .88
Age (per year increase) 1.04 (1.0-1.1) < .01 1.03 (1.0-1.1) .03 1.02 (1.0-1.1) .14
Abbreviations: CI, confidence interval; DRFS, distant recurrence-free survival; HR, hazard ratio; LRFS, locoregional recurrence-free survival; OS, overall survival.
Each row represents a separate Cox model.
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addition to concerns regarding patients who were lost to
follow-up. More robust prospective data that uses the AJCC
eighth edition a priori is needed to more definitively address
questions of selection criteria for treatment deintensification.
Statistical analysis was also complicated by the low number of
patients and events within certain group stages. This resulted
from nonuniform distribution of patients among the AJCC
seventh edition clinical stages, which highlights a significant
shortcoming of that system. Another limitation to this study is
the inclusion of patients whose specimens were positive for
HPV DNA but for whom p16 status was unavailable. The
AJCC eighth edition stipulates that p16 staining should be
used to determine the HPV-relatedness of oropharyngeal can-
cers. However, a significant number of patients in this analysis
were diagnosed before p16 staining was routinely performed
at our institution. Although HPV DNA detection and p16-
positivity are highly correlated,23 this deviation from current
guidelines should be recognized. It is also important to note
that this study analyzed the impact of clinical stage only, and
not pathologic stage. The AJCC eighth edition has a separate
pathologic staging schema, which has been a source of early
controversy. However, as questions regarding clinical stage
and smoking history also apply to patients treated with sur-
gery, we elected to include these patients without focusing on
their pathologic stage. As a result, of course, we cannot use
these data to comment on the AJCC eighth edition surgical
staging system.
5 | CONCLUSIONS
The AJCC eighth edition clinical staging system appropri-
ately stratifies outcomes for HPV-associated oropharyngeal
SCC in terms of OS and DRFS but not LRFS. Although
smoking history was associated with worse OS in this cohort,
it did not correlate with LRFS or DRFS. These results sup-
port implementation of the AJCC eighth edition cancer stag-
ing manual for HPV-associated oropharyngeal SCC and
suggest that smoking history should not inherently exclude
patients from treatment deintensification paradigms.
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